Isis Pharmaceuticals, Inc.

Abbott Laboratories Corporation

University of California

Universitéde Montreal

Farmitalia Carlo Erba S.p.a.

Canadian Patents & Development Ltd.

Adir Et Compagnie

Farmitalia Carlo Erba S.r.l.

Achaogen, Inc.

Ionis Pharmaceuticals, Inc.

Stephen Hanessian

Eric E Swayze

Richard Holmes Griffey

Michael T Migawa

Susanta Sekhar Adhikari

Janek Szychowski

Kandasamy Pachamuthu

Dale J Kempf

Chen Zhao

Gary T Wang

Clarence J Maring

Xiaojing Wang

Kent D Stewart

Minghua Sun

Vincent L Giranda

Darold L Madigan

Vincent S Stoll

Yu Gui Gu

Aimee Edinger

Punit P Seth

Hing L Sham

Angelo Bedeschi

Allan C Krueger

Larry L Klein

Ming Clinton Yeung

Warren M Kati

Keith F McDaniel

David J Grampovnik

Paul E Wiedeman

Hui-Ju J Chen

Yuanwei Chen

William J Flosi

Xuehong Luo

Sheldon Wang

Yibo Xu

David A Degoey

Steven W Muchmore

Zhen Lin

April Kennedy

Frank L Wagenaar

Benjamin R Schroeder

Noah P Tu

Malken Bayrakdarian

Pierre Renard

Martin Sheringham Linsell

James Bradley Aggen

Daniel-Henri Caignard

Adam Aaron Goldblum

Marco Alpegiani

Ghanem Atassi

Ettore Perrone

Paola Dozzo

Micah James Gliedt

Alex M Nadzan

Ronald E Carney

Darin James Hildebrandt

Andre G Pernet

Timothy Robert Kane

Gordon Tucker

Giuseppe Meinardi

Alexandre Giguère

Justyna Grzyb

Juan Pablo Maianti

Robert D Giacometti

Bradley L Merner

Jianchio Wang

Small molecules comprised of azacyclic constrained sphingolipid-like compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.

Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment

Small molecules comprised of azacyclic constrained analogs of FTY720 are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, leukemia, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.

Azacyclic constrained analogs of FTY720

The present disclosure provides tricyclic nucleosides and oligomeric compounds prepared therefrom. The tricyclic nucleosides each have a tricyclic ribosyl sugar moiety wherein a bridge between the 2' and 4&#x2032; ribosyl ring carbon atoms further comprises a fused carbocyclic or heterocyclic ring. The tricyclic nucleosides are expected to be useful for enhancing properties of oligomeric compounds including for example binding affinity and nuclease resistance.

Tricyclic nucleic acid analogs

The present invention provides novel 3',5&#x2032;-linked bicyclic nucleosides and oligomeric compounds prepared therefrom. The bicyclic nucleosides provided herein are useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as nuclease resistance.

Bicyclic nucleosides and oligomeric compounds prepared therefrom

The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.

Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q, Q, Z, Z, Z, Z, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Antibacterial aminoglycoside analogs

The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2&#x2033;-O-position as well as their preparation and use as prophylactic or therapeutics against microbial infection.

Antimicrobial 2-deoxystreptamine compounds

Inhibitors of neuraminidases

Neuraminidase inhibitors

A compound selected from those of formula (I): ##STR1## wherein: R.sub.1 represents optionally substituted alkyl, acyl, cycloalkyl, aryl, aminocarbonylalkyl, or heterocycle,

Hydroxamic acid compounds

Compounds of the formula I ##STR1## wherein R' is a free or esterified carboxy group or a carboxylate anion and R.sup.2 is an organic group have beta-lactamase inhibition activity. A process for the preparation of the same and pharmaceutical compositions containing these compounds are provided.

Inhibition of .beta.lactamase with 6 .beta.-(substituted

Growing community of inventors

Beaconsfield, Canada

Stephen Hanessian